Phacilitate Leaders World 

Supply chain and logistics

Supply chain and logistics

Avoid Tripping at the Last Mile (webinar)

Watch this webinar to gain perspective from two global leaders with decades of experience in handling inventories of high value, cryopreserved cellular products. 

Watch it on demand


Cell and Gene Therapy Manufacturing Capacities in North America

Phacilitate's annual cell and gene therapy manufacturing capacities review reaches North America. Brought to you in partnership with Aldevron.

View the infographic


Supply chain & Logistics for Advanced Therapies

In this e-book we explore the impact of the supply chain on commercialisation and provide in depth insight and knowledge from the industry to prevent further failures and ensure the best levels of patient care can reach the market

Read the ebook


Designing a robust supply chain for ATMPs

Interview with Lars Krosch: Understanding the layers of complexity and working towards full transparency are essential to achieving a robust and agile supply chain for ATMPs

Read the interview


  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman